Boehringer Ingelheim Promeco S.A. de C.V.
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- Mexico
- Registered address
- Maiz No. 49, Barrio Xaltocan, Xochimilco, Mexico City, DF 16090, Mexico (MEX)
- Operations here
- analysislabelmanufacturepackrelabelrepack
- FDA identifiers
- FEI 1000183111 · DUNS 812579472
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- VAIDrug Quality Assurance2022-05-20
- OAIDrug Quality Assurance2019-12-06
- NAIDrug Quality Assurance2017-12-08
- NAIDrug Quality Assurance2015-11-20
- NAIDrug Quality Assurance2013-06-25
Drugs this plant is listed as making
5 distinct drugs across 13 products name this site in their FDA label.
- EmpagliflozinBoehringer Ingelheim Pharmaceuticals, Inc.
- empagliflozin and metformin hydrochlorideBoehringer Ingelheim Pharmaceuticals, Inc.
- linagliptinBoehringer Ingelheim Pharmaceuticals, Inc.
- linagliptin and metformin hydrochlorideBoehringer Ingelheim Pharmaceuticals, Inc.
- telmisartan and hydrochlorothiazideBoehringer Ingelheim Pharmaceuticals, Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.